Effectiveness of pegylated interferon [peginterferon-alpha-2a] plus ribavirin in the treatment of active and past intravenous drug users infected with hepatitis C

Trial Profile

Effectiveness of pegylated interferon [peginterferon-alpha-2a] plus ribavirin in the treatment of active and past intravenous drug users infected with hepatitis C

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2013

At a glance

  • Drugs Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Aug 2013 Results published in Clinical Infectious Diseases.
    • 03 Aug 2011 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
    • 03 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top